RevMAb
RevMAb Biosciences公司 RevMAb Biosciences代理 RevMAb Biosciences中國(guó)代理 RevMAb Biosciences上等代理
RevMAb Biosciences USA，Inc是一家生物技術(shù)公司，專注于利用不需要細(xì)胞融合和雜交瘤產(chǎn)生的**性技術(shù)開(kāi)發(fā)重組單克隆抗體。我們的使命是通過(guò)加速生物醫(yī)學(xué)研究和推進(jìn)**診斷來(lái)促進(jìn)個(gè)人健康。我們通過(guò)在研究和診斷領(lǐng)域?yàn)槲覀兊目蛻籼峁┥系鹊膯慰寺】贵w來(lái)實(shí)現(xiàn)這一目標(biāo)。
我們的團(tuán)隊(duì)由在商業(yè)應(yīng)用中優(yōu)化和轉(zhuǎn)化兔雜交瘤技術(shù)的先驅(qū)者，以及用于研究，診斷和**用途的兔單克隆抗體的開(kāi)發(fā)。憑借多年的抗體開(kāi)發(fā)經(jīng)驗(yàn)和強(qiáng)大的專業(yè)技術(shù)，RevMAb的科學(xué)家團(tuán)隊(duì)致力于革新抗體產(chǎn)生和開(kāi)發(fā)高質(zhì)量的產(chǎn)品，以揭示真正的科學(xué)
美國(guó)RevMAb Biosciences公司開(kāi)發(fā)了一種**性的單克隆抗體生成方法，可以在不產(chǎn)生雜交瘤的情況下開(kāi)發(fā)單克隆抗體。 抗體是從傳統(tǒng)雜交瘤技術(shù)無(wú)法獲得的廣泛范圍的抗原特異性B細(xì)胞開(kāi)發(fā)的。 這一**性的方法已被成功應(yīng)用于開(kāi)發(fā)高質(zhì)量的兔和山羊單克隆抗體。
代替目前通過(guò)細(xì)胞融合方法產(chǎn)生的雜交瘤，我們通過(guò)**測(cè)定如elisa，Western印跡等直接篩選**兔或山羊B細(xì)胞的抗體，并鑒定所需的B細(xì)胞。 然后，我們克隆cDNA并使用瞬時(shí)穩(wěn)定的哺乳動(dòng)物細(xì)胞表達(dá)進(jìn)行重組抗體生產(chǎn)。 了解關(guān)于RevMAb Biosciences和我們的服務(wù)的更多信息。
RevMAb Biosciences公司的特色 就是所有抗體都不是雜交瘤生產(chǎn)抗體 而是用*新的方法 基因重組表達(dá)抗體 優(yōu)點(diǎn)是抗體表達(dá)量高 特異性更強(qiáng)
RevMAb的重組抗體是兔子單克隆抗體，使用我們專有技術(shù)從**動(dòng)物的分離的B細(xì)胞直接開(kāi)發(fā)。 經(jīng)過(guò)廣泛的篩選后，我們克隆抗原特異性抗體H和L鏈cDNA并在哺乳動(dòng)物細(xì)胞中重組表達(dá)。 然后從無(wú)動(dòng)物源的培養(yǎng)上清液中大規(guī)模生產(chǎn)抗體，然后蛋白A親和純化。
Revolutionary mAb Technology
RevMAb Biosciences USA, Inc has developed a revolutionary monoclonal antibody generation method which allows development of monoclonal antibodies without generation of hybridoma. The recombinant antibodies are developed from a broad range of antigen-specific B cells that are inaccessible to traditional hybridoma technology. This revolutionary method has successfully been applied to develop high quality recombinant rabbit and goat monoclonal antibodies.
RevMAb Biosciences USA, Inc is a biotechnology company focused on the development of recombinant monoclonal antibodies using a revolutionary technology that does not require cell fusion and hybridoma generation. Our mission is to promote personal health by accelerating biomedical research and advancing disease diagnosis. We seek to accomplish this by providing superior monoclonal antibodies to our customers in the research and diagnostic fields.
Our team consists of pioneers in optimizing and transforming rabbit hybridoma technology for commercial application, and developing rabbit monoclonal antibodies for research, diagnostic and therapeutic use. With years of experience and strong expertise in antibody development, RevMAb’s team of scientists aim to revolutionize antibody generation and develop high quality products in order to reveal true science. For more information please contact us.
